Should sunitinib still be used in the treatment of metstatic kidney cancer?
The impact of p53 mutation on survival in EGFR-mutated NSCLC patients
Results of TRIAS 2009 trial of sorafenib with topotecan in ovarian cancer
Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients
Gilberto De Castro Jr
Progression is progression! The importance of monitoring the efficacy of immunotherapy in NSCLC